Trials / Completed
CompletedNCT05199337
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis.
Detailed description
A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis. The first part of the study is phase 1 dose-escalation and the second part will be phase 2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZN-d5 | ZN-d5 will be administered orally |
Timeline
- Start date
- 2021-11-30
- Primary completion
- 2024-02-14
- Completion
- 2024-02-14
- First posted
- 2022-01-20
- Last updated
- 2024-09-19
Locations
21 sites across 7 countries: United States, Australia, Cyprus, Greece, Israel, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05199337. Inclusion in this directory is not an endorsement.